Anti-CD22 Therapy in HCL: Moxetumomab Pasudotox - OncLive
Anti-CD22 Therapy in HCL: Moxetumomab Pasudotox OncLive
Key opinion leaders elucidate the rationale and data behind moxetumomab pasudotox, an anti-CD22 therapy available for patients with hairy cell leukemia ...
Comments
Post a Comment